SCHEMBL6665657

SCHEMBL6665657

CN1C(=O)C(Cc2ccccc2)C(=O)c2cc(C(=O)NCc3ccccc3)ccc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.60
GAA P10253 2/20 0.52
MEN1 O00255 1/20 0.52
TSHR P16473 1/20 0.52
KMT2A Q03164 1/20 0.52
DRD2 P14416 2/20 0.51
BRD4 O60885 1/20 0.46
HPGD P15428 1/20 0.46
THRB P10828 1/20 0.45
LMNA P02545 2/20 0.45
KDM4E B2RXH2 1/20 0.45
GLA P06280 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MAPK1 P28482 1/20 0.45
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44
RAB9A P51151 1/20 0.43
HDAC2 Q92769 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6678354 0.92 DRD2 (0.54) ALDH1A1MEN1KMT2ADRD2THRB
SCHEMBL6684556 0.86 DRD2 (0.49) ALDH1A1GAAMEN1KMT2ADRD2
SCHEMBL6678968 0.86 NR1H2 (0.49) ALDH1A1MEN1KMT2AHPGDKDM4E
SCHEMBL6666902 0.85 TP53 (0.47) ALDH1A1MEN1KMT2ADRD2BRD4
SCHEMBL6685126 0.84 THRB (0.48) ALDH1A1DRD2BRD4THRBTP53
SCHEMBL6664679 0.83 SMN1; SMN2 (0.51) ALDH1A1DRD2SMN1; SMN2MAPK1MAPT
SCHEMBL6681355 0.83 HTR7 (0.49) ALDH1A1GAADRD2BRD4LMNA
SCHEMBL6664648 0.82 ALDH1A1 (0.49) ALDH1A1DRD2THRBLMNAMAPK1
SCHEMBL6686372 0.82 ALDH1A1 (0.49) ALDH1A1KMT2ADRD2SMN1; SMN2MAPK1
SCHEMBL6664863 0.81 DRD2 (0.46) ALDH1A1DRD2BRD4THRBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors HICKS JAMES LESTER (US) 2004-03-04 US disclosed
WO-2004014388-A1 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors MMP13, MMP26, MMP9 ALDH1A1 1202/4885GAA 554/4885MEN1 3612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.